Array BioPharma (ARRY) Set to Announce Quarterly Earnings on Thursday
Array BioPharma (NASDAQ:ARRY) is set to issue its quarterly earnings data on Thursday, October 31st. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Array BioPharma (NASDAQ:ARRY) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.07. The company had revenue of $25.40 million for the quarter, compared to the consensus estimate of $16.13 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was up 22.7% on a year-over-year basis. On average, analysts expect Array BioPharma to post $-0.71 EPS for the current fiscal year and $-0.62 EPS for the next fiscal year.
Shares of Array BioPharma (NASDAQ:ARRY) opened at 5.63 on Wednesday. Array BioPharma has a one year low of $3.25 and a one year high of $7.10. The stock has a 50-day moving average of $6.1 and a 200-day moving average of $5.39. The company’s market cap is $658.8 million.
A number of research firms have recently commented on ARRY. Analysts at Jefferies Group raised their price target on shares of Array BioPharma from $7.00 to $8.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Array BioPharma from $7.00 to $8.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. Five investment analysts have rated the stock with a buy rating, Array BioPharma presently has a consensus rating of “Buy” and a consensus target price of $7.67.
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.